Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Depreciation & Amortization (CF) (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $901000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 38.92% year-over-year to $901000.0, compared with a TTM value of $6.4 million through Sep 2025, up 9.59%, and an annual FY2024 reading of $5.8 million, up 6.83% over the prior year.
  • Depreciation & Amortization (CF) was $901000.0 for Q3 2025 at Barinthus Biotherapeutics, down from $2.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.0 million in Q1 2025 and bottomed at $85000.0 in Q3 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.1 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) soared 1297.65% in 2022, then crashed 38.92% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $321000.0 in 2021, then skyrocketed by 266.67% to $1.2 million in 2022, then grew by 21.92% to $1.4 million in 2023, then fell by 0.49% to $1.4 million in 2024, then crashed by 36.9% to $901000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BRNS at $901000.0 in Q3 2025, $2.0 million in Q2 2025, and $2.0 million in Q1 2025.